Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?

Muzaffer Onur Turan Nalan Ogan Fulsen Bozkus Nurhan Sarıoğlu Pakize Ayşe Turan Celal Satıcı

Published in: European journal of clinical pharmacology (2024)

According to significant improvements in CAT and SGRQ score, LAMA may be preferred over LABA as a bronchodilator agent in group A COPD patients, especially in emphysema-dominant phenotype.

Keyphrases

end stage renal disease
chronic obstructive pulmonary disease
ejection fraction
newly diagnosed
chronic kidney disease
lung function
prognostic factors
cystic fibrosis
idiopathic pulmonary fibrosis
duchenne muscular dystrophy